Evidence map›Paper›PMID 33230260›Full record

ArticleCell death and differentiation2021

Necroptosis is dispensable for the development of inflammation-associated or sporadic colon cancer in mice.

Silvia Alvarez-Diaz, Adele Preaudet, Andre L Samson, Paul M Nguyen, Ka Yee Fung, Alexandra L Garnham, Warren S Alexander, Andreas Strasser, Matthias Ernst, Tracy L Putoczki and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Metabolic cell death in cancer: mechanisms and therapeutic potential.Apoptosis : an international journal on programmed cell death · 2025
    Pooled it
  2. MMP14-Dependent Activation of TGF-β Signaling Enhances Malignancies via Promoting Necroptosis in Glioblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Vitamin DCancers · 2024
    Article
  10. Inflammation and tumor microenvironment.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Necroptosis pathways in tumorigenesis.Seminars in cancer biology · 2022
    Review
  16. Article
  17. Necroptosis in inflammatory bowel disease: A potential effective target.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Silvia Alvarez-DiazThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Adele PreaudetThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Andre L SamsonThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0002-0637-2716
Paul M NguyenThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Ka Yee FungThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Alexandra L GarnhamThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Warren S AlexanderThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Andreas StrasserThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Matthias ErnstOlivia Newton-John Cancer Research Institute, and La Trobe University School of Cancer Medicine, Heidelberg, VIC, 3084, Australia.ORCID http://orcid.org/0000-0002-6399-1177
Tracy L Putoczki *The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia. putoczki.t@wehi.edu.au.
James M Murphy *The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia. jamesm@wehi.edu.au.ORCID http://orcid.org/0000-0003-0195-3949
The University of Melbourne · AULa Trobe University · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 1058344Department of Health | National Health and Medical Research Council (NHMRC) 1113133Department of Health | National Health and Medical Research Council (NHMRC) 1113577Department of Health | National Health and Medical Research Council (NHMRC) 1116937Department of Health | National Health and Medical Research Council (NHMRC) 1124735Department of Health | National Health and Medical Research Council (NHMRC) 1124737Department of Health | National Health and Medical Research Council (NHMRC) 1143105Department of Health | National Health and Medical Research Council (NHMRC) 1172929Department of Health | National Health and Medical Research Council (NHMRC) 461221
6 · The paper itself

Abstract

Chronic inflammation of the large intestine is associated with an increased risk of developing colorectal cancer (CRC), the second most common cause of cancer-related deaths worldwide. Necroptosis has emerged as a form of lytic programmed cell death that, distinct from apoptosis, triggers an inflammatory response. Dysregulation of necroptosis has been linked to multiple chronic inflammatory diseases, including inflammatory bowel disease and cancer. Here, we used murine models of acute colitis, colitis-associated CRC, sporadic CRC, and spontaneous intestinal tumorigenesis to investigate the role of necroptosis in these gastrointestinal pathologies. In the Dextran Sodium Sulfate-induced acute colitis model, in some experiments, mice lacking the terminal necroptosis effector protein, MLKL, or its activator RIPK3, exhibited greater weight loss compared to wild-type mice, consistent with some earlier reports. However, the magnitude of weight loss and accompanying inflammatory pathology upon Mlkl deletion varied substantially between independent repeats. Such variation provides a possible explanation for conflicting literature reports. Furthermore, contrary to earlier reports, we observed that genetic deletion of MLKL had no impact on colon cancer development using several mouse models. Collectively, these data do not support an obligate role for necroptosis in inflammation or cancer within the gastrointestinal tract.

Indexed as

AnimalsColonic NeoplasmsDisease Models, AnimalInflammationMiceNecroptosis

Identifiers

PMID33230260
PMCPMC8167101
OpenAlexW3108330280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.